MacroGenics Inc
MGNX1.450USD
-0.130-8.23%
Fechamento 11/04, 16:00（ET）Cotações atrasadas em 15 min
91.65MValor de mercado
PerdaP/L TTM
Mais detalhes de MacroGenics Inc Empresa
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Informações de MacroGenics Inc
Código da empresaMGNX
Nome da EmpresaMacroGenics Inc
Data de listagemOct 10, 2013
CEOMr. Eric Risser
Número de funcionários341
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 10
Endereço9704 Medical Center Drive
CidadeROCKVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20850
Telefone13012515172
Sitehttps://www.macrogenics.com/
Código da empresaMGNX
Data de listagemOct 10, 2013
CEOMr. Eric Risser
Executivos da empresa MacroGenics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
111.00K
+909.09%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Dr. Ezio Bonvini, M.D.
Dr. Ezio Bonvini, M.D.
Senior Vice President - Research, Chief Scientific Officer
Senior Vice President - Research, Chief Scientific Officer
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Mr. Eric Risser
Mr. Eric Risser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jeffrey Peters
Mr. Jeffrey Peters
Senior Vice President, General Counsel, Corporate Compliance Officer
Senior Vice President, General Counsel, Corporate Compliance Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
111.00K
+909.09%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 17 de ago
Atualizado em: dom, 17 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Bellevue Asset Management AG
15.69%
Armistice Capital LLC
9.43%
The Vanguard Group, Inc.
6.67%
Wasatch Global Investors Inc
5.14%
Frazier Life Sciences Management, L.P.
5.02%
Outro
58.04%
Investidores
Investidores
Proporção
Bellevue Asset Management AG
15.69%
Armistice Capital LLC
9.43%
The Vanguard Group, Inc.
6.67%
Wasatch Global Investors Inc
5.14%
Frazier Life Sciences Management, L.P.
5.02%
Outro
58.04%
Tipos de investidores
Investidores
Proporção
Investment Advisor
28.88%
Investment Advisor/Hedge Fund
19.79%
Hedge Fund
18.93%
Private Equity
5.02%
Research Firm
4.22%
Individual Investor
3.34%
Pension Fund
0.11%
Venture Capital
0.02%
Outro
19.67%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
334
48.66M
76.98%
-24.24M
2025Q2
349
54.16M
85.84%
-24.12M
2025Q1
365
56.04M
88.82%
-21.64M
2024Q4
367
57.72M
91.98%
-20.16M
2024Q3
367
57.51M
91.64%
-21.39M
2024Q2
370
63.01M
100.47%
-16.59M
2024Q1
368
67.02M
107.12%
-8.36M
2023Q4
353
64.08M
103.25%
-12.72M
2023Q3
352
60.31M
97.24%
-15.19M
2023Q2
356
62.23M
100.48%
-18.91M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Bellevue Asset Management AG
9.92M
15.69%
-9.97K
-0.10%
Jun 30, 2025
Armistice Capital LLC
5.96M
9.43%
-336.00K
-5.34%
Jun 30, 2025
The Vanguard Group, Inc.
4.21M
6.67%
-212.88K
-4.81%
Jun 30, 2025
Wasatch Global Investors Inc
3.25M
5.14%
+774.00
+0.02%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
3.18M
5.02%
--
--
Jun 30, 2025
Acadian Asset Management LLC
2.49M
3.94%
+183.05K
+7.93%
Jun 30, 2025
Millennium Management LLC
2.02M
3.19%
+291.61K
+16.91%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.74M
2.76%
-2.76M
-61.25%
Jun 30, 2025
EcoR1 Capital, LLC
1.60M
2.54%
+1.60M
--
Jun 30, 2025
Koenig (Scott)
1.43M
2.26%
+52.83K
+3.85%
Aug 13, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Direxion Daily S&P Biotech Bull 3X Shares
0%
SPDR S&P Biotech ETF
0%
Humankind US Stock ETF
0%
Proshares Ultra Russell 2000
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.02%
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
Invesco Nasdaq Biotechnology ETF
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0%
SPDR S&P Biotech ETF
Proporção0%
Humankind US Stock ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
